Skip to main content
SpringerLink
Log in
Book cover

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz pp 105–112Cite as

Hämatopoetische Stammzellen

Haematopoietic stem cell preparations

Zulassung und Qualitätskontrollen

Marketing authorisation and quality control

  • Chapter

  • 12 Accesses

Zusammenfassung

Präparationen hämatopoetischer Stammzellen bieten prinzipiell eine unendliche Vielfalt klinischer Anwendungsmöglichkeiten und Zukunftsperspektiven. Sie sind die Basis für Stammzelltransplantationen, d.h. für die Wiederherstellung der Hämatopoese nach hochdosierter zytotoxischer Therapie und bilden die Grundlage der Behandlung immunologischer Mangelsyndrome sowie erblicher Stoffwechselkrankheiten. Weiterhin könnten sie in der Zukunft ein Transportvehikel für die Gentherapie darstellen. Stammzellen können vom Knochenmark, vom peripheren Blut oder aus Nabelschnurblut gewonnen werden. Der vorliegende Artikel vermittelt einen Überblick über die Biologie der Stammzellen über, Verfahren ihrer Gewinnung, die gesetzliche Grundlage für die Herstellung von Stammzellpräparationen sowie über die Grundzüge der Anforderungen für deren Zulassung. Nach der deutschen Rechtslage sind Stammzellen dann zulassungspflichtige Arzneimittel, wenn sie nicht für eine bestimmte erkrankte Person hergestellt werden, sondern im voraus produziert und — bis zu ihrem Gebrauch — in sogenannten Zellbanken gelagert werden.

Summary

In principle, haematopoietic stem cell preparations offer a paramount array of clinical opportunities and future perspectives. They are the basis for stem cell transplantation, e.g. for rescue of haematopoiesis after high dose cytotoxic therapy, for treatment of immunologic deficiencies and congenital metabolic disorders, and, in the future, a vehicle for gene therapy. Stem cells may be obtained from bone marrow, peripheral blood, or umbilical cord blood. This article provides an overview of the biology of stem cells, procedures for their collection, the legal basis for the manufacture of stem cell preparations, and essential requirements for their marketing authorisation. According to German legislation, stem cell preparations are medicinal products necessitating a marketing authorisation, if they are not produced for a certain ill person, but manufactured beforehand and banked until needed.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   199.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Metcalf D, Moore MAS (1971) Haemotopoietic cells. Amsterdam: North Holland, pp 362–447.

    Google Scholar 

  2. Dexter TM, Coutinho LH, Spooncer E, et al. (1990) Stromal cells in hemopoiesis. In: Bock G, March J (eds) Molecular control of hemopoiesis. Wiley and Sons, Sussex, UK, pp 76–86.

    Google Scholar 

  3. Abramson S, Miller RG, Philips RA (1997) The identification in adult marrow of pluripotent and restricted stem cells of the myeloid and lymphoid systems. J Exp Med 145: 1567–1579.

    Article  Google Scholar 

  4. Philips R (1991) Hematopoietic stem cells: concepts, assays, and controversies. Sem Immunol 3:337–347.

    Google Scholar 

  5. Morrison S, Uchida N, Weissman I (1995) The biology of hematopoietic stem cells. Annu Rev Cell Dev Biol 11:35–71.

    Article  CAS  PubMed  Google Scholar 

  6. Thomas ED (1982) The role of marrow transplantation in the eradication of malignant disease. Cancer 49:1963–1969.

    Article  CAS  PubMed  Google Scholar 

  7. Bortin MM, Horowitz MM, Rimm AA (1992) Increasing utilization of allogeneic bone marrow transplantation. Results of the 1988–1990 survey. Ann Intern Med 116: 505–512.

    Article  CAS  PubMed  Google Scholar 

  8. Thomas ED (1991) Frontiers in bone marrow transplantation. Blood Cells 17:259–267.

    CAS  PubMed  Google Scholar 

  9. Marmont AM (1993) New frontiers for allogeneic bone marrow transplantation. Bone Marrow Transplant 11:3–10.

    PubMed  Google Scholar 

  10. Übersicht in: Lu L, Shen RN, Broxmeyer HE (1996) Stem cells from bone marrow, umbilical cord blood and peripheral blood for clinical application: current status and future application. Critical Reviews in: Oncology/Hematology 22:61–78.

    CAS  Google Scholar 

  11. Baumann I, Testa NG, Lange C, et al. (1993) Haemopoietic cells mobilised into the circulation by lenograstim as alternative to bone marrow for allogeneic transplants. Lancet 341:369–372.

    Article  CAS  PubMed  Google Scholar 

  12. Williams SF, Bitran JD, Richards JM, et al. (1990) Peripheral blood-derived stem cell collections for use in autologous transplantation after high dose chemotherapy: an alternative approach. Bone Marrow Transplant 5:129–133.

    CAS  PubMed  Google Scholar 

  13. Kotasek D, Shepherd KM, Sage RE, et al. (1992) Factors affecting blood stem cell collections following high-dose cyclophosphamide mobilization in lymphoma, myeloma and solid tumors. Bone Marrow Transplant 9:11–17.

    CAS  PubMed  Google Scholar 

  14. Sheridan WP, Begley CG, Juttner CA, et al. (1992) Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 339:640–644.

    Article  CAS  PubMed  Google Scholar 

  15. Kanz L, Brugger W, Mertelsmann R (1992) Mobilization of peripheral blood progenitor cells by hemopoietic growth factors following standard dose chemotherapy. Bone Marrow Transplant 10:6–10.

    Google Scholar 

  16. Kritz A, Crown JP, Motzer RJ, et al. (1993) Beneficial impact of peripheral blood progenitor cells in patients with metastatic breast cancer treated with high-dose chemotherapy plus granulocyte-macrophage colony-stimulating factor. A randomized trial. Cancer 71:2515–2521.

    Article  CAS  PubMed  Google Scholar 

  17. Teshima T, Inaba S, Harada M, et al. (1992) Cytotoxic drug and cytotoxic drug/G-CSF mobilization of peripheral blood stem cells and their use for autografting. Bone Marrow Transplant 10:215–220.

    CAS  PubMed  Google Scholar 

  18. Übersicht in: Gale RP, Henon P, Juttner C (1992) Blood stem cell transplants come of age. Bone Marrow Transplant 9:151–155.

    CAS  PubMed  Google Scholar 

  19. Chao NJ, Schriber JR, Grimes K, et al. (1993) Granulocyte colony-stimulating factor „mobilized“peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood 81:2031–2033.

    CAS  PubMed  Google Scholar 

  20. Broxmeyer HE, Douglas DW, Hangoc G, et al. (1989) Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells. Proc Natl Acad Sci USA 86:3838–3832.

    Article  Google Scholar 

  21. Gluckman E, Broxmeyer HE, Auerbach A, et al. (1989) Hematopoietic reconstitution in a patient with Fanconi’s anemia by means of umbilical cord blood from an HLA-identical sibling. N Engl J Med 321:1174–1178.

    Article  CAS  PubMed  Google Scholar 

  22. Wagner JE, Kernan NA, Steinbach M, et al. (1995) Allogeneic sibling cord blood transplantation in forty-four children with malignant and non-malignant disease. Lancet 346:214–219.

    Article  CAS  PubMed  Google Scholar 

  23. Kurtzberg J, Laughlin M, Graham ML, et al. (1996) Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. New Engl J Med 335:157–166.

    Article  CAS  PubMed  Google Scholar 

  24. Broxmeyer HE, Hangoc G, Cooper S (1992) Clinical and biological aspects of human umbilical cord blood as a source of transplantable hematopoietic stem and progenitor cells. Bone Marrow Transpl 9:7–10.

    Google Scholar 

  25. Wagner JE, Rosenthal J, Sweetman R, et al. (1995) Successful transplantation of HLA-matched and HLO-mismatched umbilical cord blood from unrelated donors: anlaysis of engraftment and acute graft-versus-host disease. Blood 88:795–802.

    Google Scholar 

  26. Gluckmann E, Rocha V, Boyer-Chammard A, et al. (1997) Outcome of cord blood transplantation from related and unrelated donors. New Engl J Med 337:373–381.

    Article  Google Scholar 

  27. Broxmeyer HE, Hangoc G, Cooper S, et al. (1992) Growth charcteristics and expansion of human umbilical cord blood and estimation of its potential for transplantation in adults. Proc Natl Acad Sci USA 89:4109–4113.

    Article  CAS  PubMed  Google Scholar 

  28. Hows JM, Bradley BA, Marsh JCW, et al. (1992) Growth of human umbilical cord blood in long-term haemopoietic cultures. Lancet 340:73–76.

    Article  CAS  PubMed  Google Scholar 

  29. Stiehm ER, Sztein MB, Steeg PS, et al. (1984) Deficient DR antigen expression on human cord blood monocytes: reversal with lymphokines. Clin Immunol Immunopathol 30:430–436.

    Article  CAS  PubMed  Google Scholar 

  30. Taylor S, Bryson YJ (1985) Impaired production of %-interferon by newborn cells in vitro is due to functionally immature macrophage. J Immunol 134:1493–1497.

    CAS  PubMed  Google Scholar 

  31. Anderson U, Bird AG, Britton S, et al. (1981) Humoral and cellular immunity in human studied at the cell level from birth to two years of age. Immunol Rev 57:5–38.

    Article  Google Scholar 

  32. Foa R, Giubellino MC, Fierro MT, et al. (1984) Immature T lymphocytes in human cord blood identified by monoclonal antibodies: a model for the study of the differentiation pathway of T cells in humans. Cell Immunol 89:194–201.

    Article  CAS  PubMed  Google Scholar 

  33. Gabbianelli M, Broccoli G, Cianetti L, et al. (1990) HLA expression in hematopoietic development. Class I and II antigens are induced in the definitive erythroid lineage and differentially modulated by fet al liver cytokines. J Immunol 144:3354–3360.

    CAS  PubMed  Google Scholar 

  34. Gale RP (1992) Fet al liver transplants. Bone Marrow Transplant 9:118–120.

    PubMed  Google Scholar 

  35. Touraine JL, Roncarlo MG, Royo C, et al. (1987) Fet al tissue transplantation, bone marrow transplantation and prospective gene therapy in severe immunodeficiencies and enzyme deficiencies. Thymus 10:75–87.

    CAS  PubMed  Google Scholar 

  36. Gluckman E, Devergie A, Thierry D, et al. (1992) Clinical applications of stem cell transfusion from cord blood and rationale for cord blood banking. Bone Marrow Transplant 9: 114–117.

    PubMed  Google Scholar 

  37. Gluckman E, Wagner J, Hows J et al. (1993) Cord blood banking for hematopoietic stem cell transplantation: an international cord blood transplant registry. Bone Marrow Transplant 11:199–200.

    CAS  PubMed  Google Scholar 

  38. Rubinstein R, Rosenfield RE, Adamson JW, et al. (1993) Stored placental blood for unrelated bone marrow reconstitution. Blood 81: 1679–1690.

    CAS  PubMed  Google Scholar 

  39. Silberstein LE, Jefferles LC (1996) Placentalblood banking — a new frontier in transfusion medicine. N Engl J Med 335:199–201.

    Article  CAS  PubMed  Google Scholar 

  40. Krause DS, Fackler MJ, Civin CI, et al. (1996) CD34: structure, biology, and clinical utility. Blood 87:1–13.

    CAS  PubMed  Google Scholar 

  41. Andrews R, Singer J, Bernstein I (1989) Precursors of colony-forming cells in humans can be distinguished from colony-forming cells by expression of CD33 and CD34 antigen by light scatter. J Exp Med 169:1721.

    Article  CAS  PubMed  Google Scholar 

  42. Jones RJ, et al. (1996) Characterization of mouse lymphohematopoietic stem cells lacking spleen colony-forming activity. Blood 88:487–491.

    CAS  PubMed  Google Scholar 

  43. Goodell MA, Brose K, Paradis G, et al. (1996) Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 183:1797–1806.

    Article  CAS  PubMed  Google Scholar 

  44. Osawa M, Hanada K, Hamada H, et al. (1996) Long-term lymphohematopoietic reconstitution by a single CD34-low/negative hematopoietic stem cell. Science 273: 242–245.

    Article  CAS  PubMed  Google Scholar 

  45. Zanjani ED, Almeida-Porada G, Livingston AG, et al. (1998) Human bone marrow CD34-negative cells engraft in vivo and undergo multilineage expression that includes giving rise to CD34-positive cells. Exp Hematol 26:353–360.

    CAS  PubMed  Google Scholar 

  46. Bhatia M, Bonnet D, Murdoch B, et al. (1998) A newly discovered class of human hematopoetic cells with SCID-repopulating activity. Nature Medicine 4:1038–1047.

    Article  CAS  PubMed  Google Scholar 

  47. Williams DA (1993) Ex vivo expansion of hematopoietic stem and progenitor cells — Robbing Peter to pay Paul? Blood 81: 3169–3172.

    CAS  PubMed  Google Scholar 

  48. Ruggieri L, Heimfeld S, Broxmeyer HE (1994) Cytokine-dependent ex-vivo expansion of early subsets of CD34 cord blood myeloid progenitors is greatly enhanced by cord blood plasma, but expansion of the more mature subsets of progenitors is favored. Blood Cells 20:436–454.

    CAS  PubMed  Google Scholar 

  49. Xiao M, Broxmeyer HE, Horie M, et al. (1994) Extensive proliferative capacity of single isolated CD34 human cord blood cells in suspension culture. Blood Cells 20:455–467.

    CAS  PubMed  Google Scholar 

  50. Williams DA (1990) Expression of introduced genetic sequences in hematopoietic cells following retroviral-mediated gene transfer. Hum Gen Therap 1:229–239.

    Article  CAS  Google Scholar 

  51. Karlsson S (1991) Treatment of genetic defects in hematopoietic cell function by gene transfer. Blood 78:2481–2492.

    CAS  PubMed  Google Scholar 

  52. Al-Lebban ZS, Henry JM, Jones JB, et al. (1990) Increased efficiency of gene transfer with retroviral vectors in neonatal hematopoietic progenitor cells. Exp Hematol 18: 180–186.

    CAS  PubMed  Google Scholar 

  53. Gesetz über den Verkehr mit Arzneimitteln (Arzneimittelgesetz). BgBI. IS. 2445 vom 24. August 1976 in der geltenden Fassung.

    Google Scholar 

  54. Gesetz zur Regelung des Transfusionswesens (Transfusionsgesetz — TFG). BGBI. IS. 1752 vom 6Juli 1998.

    Google Scholar 

  55. Betriebsverordnung für pharmazeutische Unternehmer (PharmBetrV). BgBI. IS. 546 vom 8. März 1985 in der geltenden Fassung.

    Google Scholar 

  56. Recommendation No R (95) 15 on the preparation, use and quality assurance of blood components. Council of Europe, 5. Ausgabe, 1998.

    Google Scholar 

  57. Empfehlung des Rates über die Eignung von Blut-und Plasmaspendern und das Screening von Blutspenden in der Europäischen Gemeinschaft. Amtsblatt der Europäischen Gemeinschaften, L203, S. 14-26 vom 21.7.1998.

    Google Scholar 

  58. Kommission der Europäischen Gemeinschaften (1990) Leitfaden einer guten Herstellungspraxis für Arzneimittel, mit ergänzenden Leitlinien. In: Die Regelung der Arzneimittel in der Europäischen Gemeinschaft, Band IV, Amt für amtliche Veröffentlichungen der Europäischen Gemeinschaften.

    Google Scholar 

  59. Richtlinie der Kommission zur Festlegung der Grundsätze und Leitlinien der Guten Herstellungspraxis (GMP) für zur Anwendung beim Menschen bestimmten Arzneimittel. (91/356/WEWG) vom 13.06.1991.

    Google Scholar 

  60. Richtlinien zur Blutgruppenbestimmung und Bluttransfusion (Hämotherapie). Aufgestellt vom Wissenschaftlichen Beirat der Bundesärztekammer und vom Paul-Ehrlich-In-stitut. Bundesgesundhbl 1996; 39:468-489.

    Google Scholar 

  61. Richtlinien für die allogene Knochenmarktransplantation mit nichtverwandten Spendern. Aufgestellt vom Wissenschaftlichen Beirat der Bundesärztekammer. Dt Ärztebl 1994;91:A761-766.

    Google Scholar 

  62. Richtlinien zur Transplantation peripherer Blutstammzellen. Aufgestellt vom Wissenschaftlichen Beirat der Bundesärztekammer unter Mitwirkung des Paul-Ehrlich-Institutes. Dt Ärztebl 1997; 94: A1584-1592.

    Google Scholar 

  63. Richtlinien zur Transplantation von Stammzellen aus Nabelschnurblut (CB=Cord Blood). Aufgestellt vom Wissenschaftlichen Beirat der Bundesärztekammer und vom Paul-Ehrlich-Institut (in Vorbereitung).

    Google Scholar 

  64. Richtlinien zum Gentransfer in menschliche Körperzellen. Richtlinien des ständigen Arbeitskreises „Biomedizinische Ethik und Technologiefolgenabschätzung“ beim Wissenschaftlichen Beirat der Bundesärztekammer. Dt Ärztebl 1995; 92: B583-588.

    Google Scholar 

  65. Proposed approach to regulation of cellular and tissue-based products. Docket No. 97N-0068,28.02.1997.

    Google Scholar 

  66. Guidance for human somatic cell therapy and gene therapy. März 1998.

    Google Scholar 

  67. Mittl.98/C229/03 der Kommission des Europäischen Rates.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Paul-Ehrlich-Institut, Abteilung Hämatologie und Transfusionsmedizin, Paul-Ehrlich-Straße51-59, D-63225, Langen, Deutschland

    Dr. Helga Marie Huber, M. Heiden & R. Seitz

Authors
  1. Dr. Helga Marie Huber
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Heiden
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Seitz
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Huber, H.M., Heiden, M., Seitz, R. (1999). Hämatopoetische Stammzellen. In: Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-38283-7_21

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-38283-7_21

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-37515-0

  • Online ISBN: 978-3-662-38283-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation